Mizuho Raises DexCom (DXCM) Price Target to $90 from $78 After Earnings Beat

robot
Abstract generation in progress

Mizuho analyst Anthony Petrone raised DexCom’s (DXCM) price target to $90 from $78, maintaining an Outperform rating following a strong fourth-quarter earnings beat. The company reported $1.26 billion in Q4 revenue and provided an optimistic 2026 revenue guidance of $5.16 billion to $5.25 billion, expecting significant margin expansion due to efficiency improvements and product mix. DexCom, a medical device company specializing in continuous glucose monitoring, anticipates sustained double-digit revenue growth and improved profitability.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
  • Pin

Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate App
Community
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)